RxDoctor Payments DataLook up a doctor →

Steven Brooks, DO

Procedural Dermatology · Massapequa, NYNPI 1073800165

Payments from drug & device makers

$27,674in general payments, 2019–2025

Across 948 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$4K
  • Arcutis Biotherapeutics, Inc.$3K
  • Medimetriks Pharmaceuticals, Inc.$2K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Teladoc Health, Inc.$1K
  • plus $13K from 35 others

What the payments were for

  • Consulting fees$6,63024%
  • Speaking & faculty fees$1,5756%
  • Travel & lodging$4001%
  • Food & beverage$18,52667%
  • Education$5432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,674 in reported general payments places this provider in the 75th percentile of 69 procedural dermatology providers in New York.

See all procedural dermatology providers in New York

Medicare billing

Part B allowed, 2024
$133,398
Medicare patients
270
Services billed
1,442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast14$69,975
Dupixent PenDupilumab16$58,197
Tretinoin37$2,826
Tacrolimus17$2,518
Ketoconazole90$1,617
Betamethasone Dipropionate28$1,304
Clobetasol Propionate26$1,259
Alclometasone Dipropionate28$1,155
Triamcinolone Acetonide78$772
Ammonium Lactate37$721
Hydrocortisone22$697
Metronidazole17$657
Mupirocin58$418
Fluocinonide11$372
Clotrimazole13$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,187$69,97514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 69 procedural dermatology providers in New York.

Other procedural dermatology in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →